The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Avidity Biosciences Inc shares valued at $4,843,979 were sold by MacLean Michael F on Nov 06 ’24. At $45.56 per share, MacLean Michael F sold 106,319 shares. The insider’s holdings dropped to 94,093 shares worth approximately $4.94 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, MICHAEL MACLEAN purchased 106,319 shares, netting a total of over 4,793,924 in proceeds.
Before that, LEVIN ARTHUR A had sold 5,000 shares from its account. In a trade valued at $233,168, the Director traded Avidity Biosciences Inc shares for $46.63 each. Upon closing the transaction, the insider’s holdings decreased to 5,000 shares, worth approximately $0.78 million.
As published in their initiating research note from Goldman on September 24, 2024, Avidity Biosciences Inc [RNA] has been a Buy and the price target has been revised to $59. Analysts at Barclays started covering the stock with ‘”an Overweight”‘ outlook in a report released in late August. As of May 03, 2024, BofA Securities has initiated its “Buy” rating for RNA. Earlier on March 14, 2024, Cantor Fitzgerald initiated its rating. Their recommendation was “an Overweight” for RNA stock.
Analyzing RNA Stock Performance
During the last five days, there has been a surge of approximately 11.13%. Over the course of the year, Avidity Biosciences Inc shares have jumped approximately 480.11%. Shares of the company reached a 52-week high of $56.00 on 11/13/24 and a 52-week low of $8.86 on 01/02/24. A 50-day SMA is recorded $45.04, while a 200-day SMA reached $34.05. Nevertheless, trading volume fell to 3.21 million shares from 1.08 million shares the previous day.
Support And Resistance Levels for Avidity Biosciences Inc (RNA)
According to the 24-hour chart, there is a support level at 47.55, which, if violated, would cause prices to drop to 42.59. In the upper region, resistance lies at 56.73. The next price resistance is at 60.95. RSI (Relative Strength Index) is 67.29 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 3.03, which suggests the price will increase in the coming days. Percent R is at 23.52%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
